Abbott Laboratories just made one of the biggest bets in modern diagnostics history — and on March 23, it cashed in the chips.
The North Chicago-based healthcare giant confirmed it has completed its acquisition of Exact Sciences, a deal that reshapes the competitive landscape of cancer screening and precision oncology diagnostics in the United States. The transaction, valued at an estimated enterprise value of $23 billion, positions Abbott as a dominant force in one of healthcare’s fastest-growing and most consequential segments.
A $23 Billion Wager on Early Detection
Under the terms of the agreement, Abbott paid $105 per common share in cash, representing a total equity value of approximately $21 billion. That’s not a small number, even for a company Abbott’s size. But the strategic logic isn’t hard to follow. Exact Sciences was already projected to generate more than $3 billion in revenue in 2025, growing at a high-teens organic rate. That kind of momentum, plugged into Abbott’s global distribution engine, is exactly what a deal like this is supposed to unlock.
The acquisition adds approximately $3 billion in incremental sales to Abbott in 2026 and is expected to accelerate the company’s sales growth that year by roughly 0.5%. There’s a short-term cost — dilution of approximately $0.20 to adjusted earnings per share in 2026 — but Abbott’s leadership appears comfortable with that tradeoff, given what’s now sitting inside the company’s diagnostics division.
What Abbott Actually Bought
It’s worth spelling out what’s in the portfolio, because it’s a serious collection. Exact Sciences brought with it Cologuard, the market-leading noninvasive colorectal cancer screening test; Oncotype DX, which helps clinicians make personalized treatment decisions for patients with early-stage breast cancer; Oncodetect, a tumor-informed molecular residual disease test designed to catch cancer recurrence; and Cancerguard, a multi-cancer early detection blood test that’s drawn considerable attention in the liquid biopsy space. That’s four distinct, commercially active products — not a pipeline promise, but a revenue-generating reality, as announced by the company.
Together, they give Abbott a commanding presence in what the company describes as the $60 billion U.S. cancer screening and precision oncology diagnostics market. “This acquisition strengthens Abbott’s leadership position and capabilities in diagnostics,” the company noted, “positioning the company to advance technologies that are more preventative, predictive and personalized.”
The Scale Argument
Here’s the thing about Abbott that makes this deal different from a typical acquisition story: the company already operates at an almost staggering scale. With 122,000 employees serving people in more than 160 countries across diagnostics, medical devices, nutritionals, and branded generic medicines, Abbott isn’t buying Exact Sciences to learn the diagnostics business. It’s buying it to accelerate something it already knows how to do.
Robert B. Ford, Abbott’s chairman and chief executive, was direct about the rationale. “Abbott’s global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments,” he said. “With the legacy and deep expertise of the Exact Sciences team, we’re ready to transform cancer care.”
That’s the kind of language executives deploy at closing ceremonies. Still, the underlying argument is credible. Distribution reach and commercial infrastructure are genuinely difficult to build from scratch, and Exact Sciences — for all its growth — was still primarily a U.S.-centric operation. Abbott changes that equation immediately.
A Diagnostics Giant Gets Bigger
The numbers that follow the deal closing are striking. With Exact Sciences now operating as a wholly owned subsidiary, Abbott’s total diagnostics sales will exceed $12 billion annually. That puts it in rare company globally — a diagnostics business of that size, with meaningful exposure to both routine testing and high-growth oncology segments, is an asset that competitors will be watching closely.
Cancer incidence, it’s worth noting, is not declining. Global rates continue to climb, driven by aging populations and a range of environmental and lifestyle factors. The market Abbott is entering — or more precisely, deepening its position in — isn’t a niche. It’s a structural growth story playing out across virtually every healthcare system on the planet.
That said, execution will matter enormously here. Integrating a company of Exact Sciences’ complexity, preserving the culture and scientific credibility that made products like Cologuard successful, and expanding internationally without losing the thread — none of that is guaranteed. Big acquisitions have a way of looking elegant on paper and messy in practice.
But if Abbott pulls it off, the bet is simple: that getting to cancer earlier is both the right thing to do and, increasingly, the business to be in. On that point, at least, the science and the spreadsheet seem to agree.
